Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/23/2013)... Switzerland and DRESDEN, Germany ... Cenix BioScience, a leading preclinical contract research ... and high content-driven pharmacology, and Debiopharm Group™ (Debiopharm), ... a focus on the development of prescription drugs ... companion diagnostics, today announced that they have signed ...
(Date:5/22/2013)... May 22, 2013 Advanced Prenatal Therapeutics (APT), ... that will help alleviate the high blood pressure and ... is expected to be the first medical device specifically ... and fetal death. Every year, preeclampsia affects ... States . It is characterized by high blood ...
(Date:5/22/2013)...  Viral hepatitis is an asymptomatic disease affecting more than ... hepatitis C are unaware they have the virus. ... the U.S. House of Representatives will take place at 10:00 ... Rayburn House Office Building in Washington, D.C. ... of Liver Diseases ( AASLD ) is pleased to participate ...
Breaking Medicine Technology:Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2Hepatitis Awareness: Bringing Attention to a Silent Epidemic 2
... 31 Accuray Incorporated, (Nasdaq:  ARAY), a global leader ... at two leading academic institutions using CyberKnife radiosurgery in ... of Texas Southwestern and Fox Chase Cancer Center, will ... American Society for Radiation Oncology (ASTRO) in San Diego ...
... of Bari, Italy, concluded that treating patients after transplantation ... and protects them from liver-related deaths. The purpose of ... of patients posttransplant who underwent antiviral therapy for recurrent ... The use in clinical practice of ...
Cached Medicine Technology:CyberKnife Radiosurgery for Early-Stage Breast Cancer 2CyberKnife Radiosurgery for Early-Stage Breast Cancer 3CyberKnife Radiosurgery for Early-Stage Breast Cancer 4CyberKnife Radiosurgery for Early-Stage Breast Cancer 5CyberKnife Radiosurgery for Early-Stage Breast Cancer 6Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2
(Date:5/23/2013)... 23, 2013 Elegance for a woman takes on ... her taste, her intrigue can often be found in the mystery ... a woman's soul is through her eyes. It is also ... is! That is why the elegance of a woman can be ... Women today, more than any other time, utilize eyewear to not ...
(Date:5/23/2013)... 2013 Aero Fulfillment Services, a national ... NewWave Biosciences to be the sole fulfillment provider for ... , Brad Cole, CEO New Wave Biosciences said, ... their central location, e-commerce experience with both of our ... end-to-end solution that will expand as our distribution grows.” ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Each month ... most innovative and stylish eco-friendly hybrids and electric cars. Nowhere ... in Los Angeles, the symbolic green car capital. Thankfully this ... Car Tour ride and drive back to Dwell on ... event. , During the first two days of Dwell ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... two-thirds of patients with high-risk neuroblastoma a common tumor ... cured using tumor-killing cancer drugs. A study published by ... Chemistry & Biology reveals a new genomic approach ... by causing cancer cells to differentiate, or convert from ... screening method, the researchers identified a compound that causes ...
Breaking Medicine News(10 mins):Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2
... Jan. 8 A proposal by the State of ... Home has prompted the 125,000-member American Legion Department of ... 2009, in order to organize and coordinate its members, ... provides more than $50,000 in direct and in-kind support ...
... Jan. 8 United Jewish Communities (UJC) and the ... $10 million to address humanitarian and social needs in ... and stand in solidarity with Israelis during the current ... the Gaza Strip. The funds will enhance programs supported ...
... in French . -->, ... McGill University Health Centre (RI MUHC) and the McGill University ... Canadian and Belgian institutions, have discovered DNA variations in a ... was published in the January issue of the journal ...
... Nassau ColiseumNEW YORK, Jan. 8 Stand Up for a ... -- a Valentine,s Day show with Barry Manilow , in ... be held on February 14th, 2009 at Nassau Coliseum, and tickets ... Ticketmaster.com or by calling Stand Up for a Cure at 212 ...
... Many companies are starting out,the new year with ... than,ever will your success be dependent on your ... To excel in 2009 and win customers, hearts ... customer,listening posts, optimizing complaint management, applying savvy market,segmentation, ...
... We hear it everywhere: "What is your carbon footprint?" ... and how can you reduce yours? It isn,t all ... and planning to bring it down.Listen to this report from ... journalists can access video, audio, text, graphics and photos for ...
Cached Medicine News:Health News:UJC and Jewish Federations of North America Commit $10 Million for Needs in Southern Israel 2Health News:McGill researchers discover gene that increases susceptibility to Crohn's disease 2Health News:McGill researchers discover gene that increases susceptibility to Crohn's disease 3Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:Marketers Share Customer-Centric Strategies for an Uncertain 2009 Economy, Feb 2-4 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: